• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Enveric Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    9/18/25 4:30:54 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENVB alert in real time by email
    false 0000890821 0000890821 2025-09-17 2025-09-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    September 17, 2025

    Date of Report (Date of earliest event reported)

     

    Enveric Biosciences, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38286   95-4484725

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    Enveric Biosciences, Inc.

    245 First Street, Riverview II, 18th Floor

    Cambridge, MA, 02142

    (Address of principal executive offices) (Zip code)

     

    Registrant’s telephone number, including area code: (239) 302-1707

     

    N/A

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common stock, par value $0.01 per share   ENVB   The Nasdaq Stock Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On September 17, 2025, Enveric Biosciences, Inc., a Delaware corporation (the “Company”) entered into warrant exercise inducement offer letters (the “Inducement Letters”) with certain institutional investors (the “Holders”) that held certain outstanding (a) Series A Warrants to purchase up to an aggregate of 1,212,499 shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), and (b) Series B Warrants to purchase up to an aggregate of 1,212,499 shares of the Company’s Common Stock, both originally issued to the Holders on February 3, 2025, at an exercise price of $3.00 per share (collectively, the “Existing Warrants”).

     

    Pursuant to the Inducement Letters, the Holders agreed to exercise for cash their Existing Warrants at a reduced exercise price of $0.915 per share in consideration for the Company’s agreement to issue in a private placement (x) new Series C Common Stock Purchase Warrants (“New Series C Warrants”) to purchase up to 2,424,998 shares of Common Stock (“New Series C Warrant Shares”) and (y) new Series D Common Stock Purchase Warrants (“New Series D Warrants” and, together with the New Series C Warrants, the “New Warrants”) to purchase up to 2,424,998 shares of Common Stock (the “New Series D Warrant Shares” and, together with the New Series C Warrant Shares, the “New Warrant Shares.”) The Company received aggregate gross proceeds of approximately $2.2 million from the exercise of the Existing Warrants by the Holders, before deducing placement agent fees and other offering expenses payable by the Company.

     

    The Company engaged H.C. Wainwright & Co., LLC (the “Placement Agent”) to act as its exclusive placement agent in connection with the transactions summarized above and have agreed to pay the Placement Agent a cash fee equal to 7.0% of the aggregate gross proceeds received from the Holders’ exercise of their Existing Warrants, as well as a management fee equal to 1.0% of the aggregate gross proceeds from the exercise of the Existing Warrants.

     

    The Company has also agreed to reimburse the Placement Agent for its expenses in connection with the exercise of the Existing Warrants and the issuance of the New Warrants of $35,000 for its non-accountable expenses, up to $50,000 for its accountable expenses and $15,950 for its clearing costs. The Company has also agreed to issue to the Placement Agent or its designees warrants (the “Placement Agent Warrants”) to purchase up to 169,750 shares of Common Stock (7.0% of the Existing Warrants being exercised) which will have the same terms as the New Series C Warrants, except the Placement Agent Warrants will have an exercise price equal to $1.1438 per share (125% of the offering price). The Placement Agent Warrants will be exercisable commencing on the Stockholder Approval Date (as defined below) and expire on the five (5)-year anniversary of the Stockholder Approval Date. The closing of the transactions contemplated pursuant to the Inducement Letters was September 18, 2025 (the “Closing Date”), which was subject to satisfaction of customary closing conditions. The Company expects to use the net proceeds from these transactions for working capital and general corporate purposes.

     

    The resale of the shares of Common Stock underlying the Existing Warrants has been registered pursuant to an existing registration statement on Form S-1, as amended (File No. 333-284277), declared effective by the Securities and Exchange Commission (the “SEC”) on January 30, 2025.

     

    The Company also agreed to file a registration statement on Form S-3 (or other appropriate form if it is not then Form S-3 eligible) providing for the resale of the New Warrant Shares issued or issuable upon the exercise of the New Warrants (the “Resale Registration Statement”), as soon as practicable (and in any event within 10 calendar days of the date of the Inducement Letters), and to use commercially reasonable efforts to have such Resale Registration Statement declared effective by the SEC within 45 calendar days following the date of the Inducement Letters (or within 75 calendar days following the date of the Inducement Letters in case of a “full review” of such registration statement by the SEC) and to keep the Resale Registration Statement effective at all times until no Holder of the New Warrants owns any New Warrants or New Warrant Shares. In the Inducement Letters, the Company agreed not to issue any shares of Common Stock or Common Stock equivalents or to file any other registration statement with the SEC (in each case, subject to certain exceptions) until 15 days after the Closing Date. The Company also agreed not to effect or agree to effect any Variable Rate Transaction (as defined in the Inducement Letters) until one (1) year after the Closing Date (subject to an exception).

     

    New Warrant Terms

     

    The following summary of certain terms and provisions of the New Warrants is not complete and is subject to, and qualified in its entirety by, the provisions of the New Warrants, the forms of which are filed as Exhibits 4.1 and 4.2 to this Current Report on Form 8-K and are incorporated herein by reference. The following description of the New Warrants is qualified in its entirety by reference to such exhibits.

     

    Duration and Exercise Price

     

    Each New Warrant will have an exercise price equal to $0.915 per share. The New Series C Warrants will be exercisable on or after the date on which stockholder approval is received (the “Stockholder Approval Date”) with respect to the issuance of the Series C Warrant Shares until the five-year anniversary thereafter. The New Series D Warrants will be exercisable on or after the Stockholder Approval Date with respect to the issuance of the Series D Warrant Shares until the 18-month anniversary thereafter. The exercise price and number of New Warrant Shares issuable upon exercise of the New Warrants are subject to customary adjustment in the event of stock dividends, stock splits, subsequent rights offerings, pro rata distributions, reorganizations, or similar events affecting the Common Stock and the exercise price.

     

    Exercisability

     

    The New Warrants will be exercisable, at the option of each Holder, in whole or in part, by delivering to the Company a duly executed exercise notice accompanied by payment in full for the number of shares of the Company’s Common Stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A Holder (together with its affiliates) may not exercise any portion of such Holder’s New Warrants to the extent that the Holder would own more than 4.99% of the outstanding Common Stock immediately after exercise, except that upon at least 61 days’ prior notice from the Holder to us, the Holder may increase the amount of ownership of outstanding stock after exercising the Holder’s New Warrants up to 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the New Warrants.

     

     

     

     

    Cashless Exercise

     

    If, at the time a Holder exercises its New Warrants, a registration statement registering the issuance of the shares of Common Stock underlying the New Warrants under the Securities Act of 1933, as amended (the “Securities Act”) is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price, the Holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the New Warrants.

     

    Fundamental Transactions

     

    In the event of any fundamental transaction, as described in the New Warrants and generally including any merger with or into another entity, sale of all or substantially all of the Company’s assets, tender offer or exchange offer, or reclassification of the Company’s Common Stock, then upon any subsequent exercise of a New Warrant, the Holder will have the right to receive as alternative consideration, for each share of the Company’s Common Stock that would have been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction, the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration receivable upon or as a result of such transaction by a Holder of the number of shares of Common Stock for which the New Warrant is exercisable immediately prior to such event. Notwithstanding the foregoing, in the event of a fundamental transaction (other than for the purposes listed in the New Warrants), the Holders of the New Warrants have the right to require the Company or a successor entity to redeem the New Warrants for cash in the amount of the Black-Scholes Value (as defined in each New Warrant) of the unexercised portion of the New Warrants concurrently with or within 30 days following the consummation of a fundamental transaction.

     

    However, in the event of a fundamental transaction which is not in the Company’s control, including a fundamental transaction not approved by its board of directors, the Holders of the New Warrants will only be entitled to receive from the Company or its successor entity, as of the date of consummation of such fundamental transaction, the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of the New Warrant that is being offered and paid to the Holders of Common Stock in connection with the fundamental transaction, whether that consideration is in the form of cash, stock or any combination of cash and stock, or whether the Holders of Common Stock are given the choice to receive alternative forms of consideration in connection with the fundamental transaction.

     

    Transferability

     

    Subject to applicable laws, a New Warrant may be transferred at the option of the Holder upon surrender of the New Warrant to the Company together with the appropriate instruments of transfer.

     

    Fractional Shares

     

    No fractional shares of Common Stock will be issued upon the exercise of the New Warrants. Rather, the number of shares of Common Stock to be issued will, at the Company’s election, either be rounded up to the next whole share or the Company will pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price.

     

    Trading Market

     

    There is no established trading market for the New Warrants, and the Company does not expect an active trading market to develop. The Company does not intend to apply to list the New Warrants on any securities exchange or other trading market. Without a trading market, the liquidity of the New Warrants will be extremely limited.

     

    Right as a Stockholder

     

    Except as otherwise provided in the New Warrants or by virtue of the Holder’s ownership of shares of Common Stock, such Holder of New Warrants does not have the rights or privileges of a Holder of Company Common Stock, including any voting rights, until such Holder exercises such Holder’s New Warrants. The New Warrants will provide that the Holders of the New Warrants have the right to participate in distributions or dividends paid on shares of Common Stock.

     

    Waivers and Amendments

     

    The New Warrants may be modified or amended or the provisions of the New Warrants waived with the Company and the Holder’s written consent.

     

    The forms of Inducement Letter, New Series C Warrant, New Series D Warrant, and the Placement Agent Warrant are attached as Exhibits 10.1, 4.1, 4.2, and 4.3, respectively. The descriptions of the terms of the Inducement Letter, New Series C Warrant, New Series D Warrant, and the Placement Agent Warrant are not intended to be complete and is qualified in its entirety by reference to such exhibits. The Inducement Letters contain customary representations, warranties and covenants by the Company which were made only for the purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.

     

    On September 17, 2025 and September 18, 2025, the Company issued press releases disclosing the transactions described in this Item 1.01, copies of which are filed as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K.

     

     

     

     

    Item 3.02 Unregistered Sales of Equity Securities.

     

    The Company issued the New Warrants and Placement Agent Warrants pursuant to the exemption from the registration requirements of the Securities Act, available under Section 4(a)(2) and/or Rule 506(b) of Regulation D promulgated thereunder and intends to issue the New Warrant Shares and Placement Agent Shares pursuant to the same exemption or pursuant to the exemption provided by Section 3(a)(9) of the Securities Act. The descriptions of the New Warrants and Placement Agent Warrants under Item 1.01 of this Form 8-K are incorporated by reference herein. The forms of the New Warrants and Placement Agent Warrants have been filed as exhibits to this Form 8-K and are incorporated by reference herein.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    4.1   Form of Series C Common Stock Purchase Warrant
    4.2   Form of Series D Common Stock Purchase Warrant
    4.3   Form of Placement Agent Warrant
    10.1   Form of Inducement Letter
    99.1   Press Release, dated September 17, 2025
    99.2   Press Release, dated September 18, 2025
    104   Cover Page Interactive Data File (embedded within Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: September 18, 2025 ENVERIC BIOSCIENCES, INC.
         
      By: /s/ Joseph Tucker
        Joseph Tucker, Ph.D.
        Chief Executive Officer

     

     

    Get the next $ENVB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENVB

    DatePrice TargetRatingAnalyst
    3/8/2022$7.00 → $0.20Buy → Hold
    Aegis Capital
    7/8/2021$7.00Buy
    Aegis Capital
    6/28/2021$6.00Buy
    Maxim Group
    More analyst ratings

    $ENVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

    Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced exercise of certain outstanding series A warrants to purchase up to an aggregate of 1,212,499 shares of common stock of the Company and series B warrants to purchase up to an aggregate of 1,212,499 shares of common stock originally issued in February 2025, having an exercise price of $3.00 per share, at a reduced exercise price of $0.915 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuan

    9/18/25 4:30:00 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

    Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding series A warrants to purchase up to an aggregate of 1,212,499 shares of common stock of the Company and series B warrants to purchase up to an aggregate of 1,212,499 shares of common stock originally issued in February 2025, having an exercise price of $3.00 per share, at a reduced exercise price of $0.915 per share. The shares of common stock issuable upon exercise of the warrants are reg

    9/17/25 9:24:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

    Research published in ACS Chemical Biology and BioDesign Research describes new approaches for producing tryptamine and MDMA-derived compounds Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the publication of two peer-reviewed research papers describing innovative bioproduction strategies for creating therapeutic compounds. While Enveric's lead candidate EB-003 is manufactured using established synthetic chemistry methods common to the pharmaceutical industry, these publications highlight the Company's broader scientific lea

    9/17/25 8:00:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Enveric Biosciences downgraded by Aegis Capital with a new price target

    Aegis Capital downgraded Enveric Biosciences from Buy to Hold and set a new price target of $0.20 from $7.00 previously

    3/8/22 9:32:53 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aegis Capital initiated coverage on Enveric Biosciences with a new price target

    Aegis Capital initiated coverage of Enveric Biosciences with a rating of Buy and set a new price target of $7.00

    7/8/21 9:31:19 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Enveric Biosciences with a new price target

    Maxim Group initiated coverage of Enveric Biosciences with a rating of Buy and set a new price target of $6.00

    6/28/21 8:59:11 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Pasqualone Frank bought $2,140 worth of shares (1,000 units at $2.14)

    4 - Enveric Biosciences, Inc. (0000890821) (Issuer)

    9/19/23 5:34:00 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENVB
    SEC Filings

    View All

    SEC Form S-3 filed by Enveric Biosciences Inc.

    S-3 - Enveric Biosciences, Inc. (0000890821) (Filer)

    9/29/25 4:30:36 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Enveric Biosciences, Inc. (0000890821) (Filer)

    9/18/25 4:30:54 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Enveric Biosciences, Inc. (0000890821) (Filer)

    9/2/25 8:30:26 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF INNOVATION OFFICER Facchini Peter J. was granted 24,717 shares, increasing direct ownership by 296% to 33,058 units (SEC Form 4)

    4 - Enveric Biosciences, Inc. (0000890821) (Issuer)

    5/12/25 5:00:16 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Coveney Kevin Michael was granted 74,150 shares, increasing direct ownership by 596% to 86,584 units (SEC Form 4)

    4 - Enveric Biosciences, Inc. (0000890821) (Issuer)

    5/12/25 5:00:20 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Tucker Joseph Edward was granted 98,866 shares, increasing direct ownership by 453% to 120,711 units (SEC Form 4)

    4 - Enveric Biosciences, Inc. (0000890821) (Issuer)

    5/12/25 5:00:06 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENVB
    Leadership Updates

    Live Leadership Updates

    View All

    Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

    Second biotechnology company to potentially out-license novel compounds from Enveric's portfolio of assets with possible significant milestone payments and royalties Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, is pleased to announce that it has signed two non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of cannabinoid-COX-2 conjugate compounds for both pharmaceutical and non-pharmaceutical applications for treatment of joint diseases. The term sheets c

    3/19/24 7:00:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    30+ year pharmaceutical industry veteran joins Enveric's executive team to lead company's financial and capital markets activities. Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, announced today the appointment of Kevin Coveney, CPA, to the position of Chief Financial Officer, effective March 13, 2023. Mr. Coveney brings 30+ years of accounting, finance, and operations experience to Enveric, having previously served as Chief Financial Officer for multiple biotechnology companies. As CFO, Mr. Coveney will be responsibl

    2/28/23 7:30:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Accomplished pharmaceutical industry leader brings to Enveric extensive experience in clinical operations, asset strategy and product development Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, announced today the appointment of Lynn Gallant to the position of Vice President, Clinical Operations. Ms. Gallant brings more than 25 years of clinical operations and trial management experience to Enveric and will work alongside Bob Dagher, M.D., Chief Medical Officer, to oversee the ongoing development of the company's EVM201

    2/23/23 7:33:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENVB
    Financials

    Live finance-specific insights

    View All

    Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

    Product Development Highlights: Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations. Started IND-enabling preclinical activities for EB-002 and completed important repeat-dose toxicology studies, genotoxicity studies, and key cardiac, respiratory, and CNS safety pharmacology studies. Corporate and Business Development Highlights: Signed three non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of three classes of compounds from the Company's extensive portfolio of assets. Signe

    3/26/24 7:00:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights

    Announced cost reduction plan resulting in approximately 40% to 55% decrease in expenses and extension of financial runway into Q1 2024 Continued to advance pipeline of small molecule therapeutics for the treatment of mental health disorders, including EB-373 for the treatment of anxiety disorder and EVM301 Series Announced termination of proposed spin-off of cannabinoid clinical development pipeline to publicly traded company; Enveric now engaging with strategic advisors to identify and pursue alternative value-creating opportunities for cannabinoid assets Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of

    5/15/23 9:25:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Announces Confidential Submission of Registration Statement for the Spin-off of its Cannabinoid Business to Shareholders

    The proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation psychedelic-inspired treatments and the other developing innovative cannabinoid treatments Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the confidential submission of a Form S-1 draft registration statement with the U.S. Securities and Exchange Commission (‘SEC') for the spin-off its cannabinoid clinical development pipeline to a wholly-owned subsidiary, Akos Biosciences, Inc. (‘Akos'),

    11/28/22 7:30:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Enveric Biosciences Inc.

    SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)

    11/14/24 4:03:47 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Enveric Biosciences Inc.

    SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)

    11/13/24 11:18:03 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Enveric Biosciences Inc.

    SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)

    11/12/24 1:43:47 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care